- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07645066
Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction (PSB-AF)
A Prospective, Multicenter, Randomized Controlled Trial Evaluating the Effect of Posterosuperior Bundle Pacing on Atrial Fibrillation Prevention in Patients With Sinus Node Dysfunction
This study aims to evaluate whether posterosuperior bundle (PSB) pacing reduces the incidence of atrial fibrillation (AF) in patients with sinus node dysfunction (SND) undergoing pacemaker implantation. Approximately 300 patients will be enrolled and randomized to receive atrial pacing at either the PSB region or the right atrial appendage (RAA). The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes, as detected by device or surface electrocardiogram. Patients will be followed for up to 24 months.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Sinus node dysfunction (SND) is a common indication for permanent pacemaker implantation. Conventional right atrial appendage (RAA) pacing may result in delayed or dyssynchronous atrial activation, potentially increasing the risk of atrial arrhythmias. Posterosuperior bundle (PSB) pacing is a novel physiological atrial pacing approach. This study is a prospective, multicenter, open-label, randomized controlled trial. A total of approximately 300 eligible SND patients indicated for pacemaker implantation will be enrolled and randomly assigned (1:1) to PSB pacing or RAA pacing. Ventricular pacing will be performed using left bundle branch area pacing in both groups. Following implantation, the pacemaker will be programmed in DDD mode with a lower rate of 70 beats/min during daytime and 60 beats/min during nighttime. Rate-responsive pacing will be enabled by default when available; ATP will be disabled by default. Participants will be followed at 3, 6, 12, and 24 months after implantation. The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes. Secondary endpoints include atrial high-rate episodes, AF burden, pacing parameters, ECG and echocardiographic indices, laboratory findings, and mortality outcomes. Safety endpoints include procedural complications and device-related adverse events.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Zhaohui Qiu
- Número de telefone: +862152039999
- E-mail: qzh3503@shtrhospital.com
Locais de estudo
-
-
Anhui
-
Anqing, Anhui, China
- Ainda não está recrutando
- China Medical University affiliated AnQing Municipal Hospital
-
Contato:
- Liangchuan Chen
- Número de telefone: +86 13956556381
- E-mail: aqslyy@163.com
-
Tongling, Anhui, China
- Ainda não está recrutando
- Tongling People's Hospital
-
Contato:
- Ying Zhang
- Número de telefone: +86 18005669636
- E-mail: tlph@mail.wh.ah.cn
-
-
Guizhou
-
Zunyi, Guizhou, China
- Ainda não está recrutando
- Affiliated Hospital of Zunyi Medical College
-
Contato:
- Xianping Long
- Número de telefone: +86 13885294999
- E-mail: longxianping1201@163.com
-
-
Hubei
-
Wuhan, Hubei, China
- Ainda não está recrutando
- Wuhan Asia General Hospital
-
Contato:
- Hongwei Han
- Número de telefone: +86 15327298622
- E-mail: wuhanagh@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200336
- Recrutamento
- Tong Ren Hospital, Shanghai Jiaotong University School of Medicine
-
Contato:
- Zhaohui Qiu
- Número de telefone: +862152039999
- E-mail: qzh3503@shtrhospital.com
-
Shanghai, Shanghai Municipality, China
- Ainda não está recrutando
- Fudan University affiliated Huadong Hospital
-
Contato:
- Zhengqi Kong
- Número de telefone: +86 13816620347
- E-mail: huadongtexu@163.com
-
Shanghai, Shanghai Municipality, China
- Ainda não está recrutando
- Shanghai Jiaotong University affiliated Shanghai Ninth People's Hospital
-
Contato:
- Zongqi Zhang
- Número de telefone: +86 18049827281
- E-mail: zqzhang_scdc@126.com
-
Shanghai, Shanghai Municipality, China
- Ainda não está recrutando
- Shanghai Jiaotong University affiliated Shanghai Sixth People's Hospital
-
Contato:
- Yisheng Pan
- Número de telefone: +86 13817273883
- E-mail: shlygjyl@163.com
-
Shanghai, Shanghai Municipality, China
- Ainda não está recrutando
- Shanghai University of Traditional Chinese Medicine affiliated Putuo Hospital
-
Contato:
- Zongjun Liu
- Número de telefone: +86 19821577439
- E-mail: lzj72@126.com
-
Shanghai, Shanghai Municipality, China
- Ainda não está recrutando
- Tongji University School of Medicine affiliated Tongji University
-
Contato:
- Bing Sun
- Número de telefone: +86 13918324334
- E-mail: woowoocncn@163.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age ≥18 years
- Indication for permanent pacemaker implantation, including:
- Sinus node dysfunction, defined as at least one of the following:
- Symptomatic sinus bradycardia
- Tachy-brady syndrome
- Chronotropic incompetence
- Sinus pause / arrest
- Atrioventricular block (if present); if ventricular pacing is required, left bundle branch area pacing is planned
- Expected survival >1 year
- Panned implantation of a device capable of detecting atrial high-rate episodes
- Willing and able to provide informed consent
Exclusion Criteria:
- Persistent atrial fibrillation (AF) (>7 days), long-standing persistent AF, permanent AF, or prior atrioventricular node ablation
- Prior cardiac implantable electronic device (CIED) requiring replacement, upgrade, or revision
- Indication for cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT-D)
- Prior cardiac surgery, severe hepatic or renal dysfunction, or other life-threatening systemic diseases
- Acute myocardial infarction within 3 months before enrollment
- Persistent left superior vena cava or dextrocardia
- Pregnant or breastfeeding women, or women of childbearing potential not using effective contraception
- Participation in another clinical trial that may interfere
- Any condition that, in the opinion of the investigator, makes participation unsuitable
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: PSB pacing
Patients were randomly assigned to receive posterosuperior bundle pacing for atrial pacing during regular pacemaker implantation procedures. |
Atrial pacing lead implanted at the posterosuperior bundle region. Left bundle branch area pacing will be applied if ventricular pacing is necessary. |
|
Comparador Ativo: RAA pacing
Patients were randomly assigned to receive right atrial appendage pacing for atrial pacing during regular pacemaker implantation procedures. |
Atrial pacing lead implanted at the right atrial appendage. Left bundle branch area pacing will be applied if ventricular pacing is necessary. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of atrial fibrillation
Prazo: From implantation to regular follow-ups up to 24 months
|
Incidence of atrial fibrillation ≥ 6 minutes during follow-ups |
From implantation to regular follow-ups up to 24 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Atrial high-rate episodes
Prazo: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
AF burden
Prazo: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
eGFR
Prazo: At baseline, before discharge, and 6 - month follow-up
|
At baseline, before discharge, and 6 - month follow-up
|
|
|
All-cause mortality
Prazo: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Cardiovascular death
Prazo: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Intrinsic P-wave duration
Prazo: At baseline and regular follow-ups up to 24 months, when intrinsic atrial rhythm is assessable
|
Measured from the onset of the P wave to the end |
At baseline and regular follow-ups up to 24 months, when intrinsic atrial rhythm is assessable
|
|
Paced P-wave duration
Prazo: From implantation to regular follow-ups up to 24 months
|
Measured from the pacing stimulus to P wave end duration |
From implantation to regular follow-ups up to 24 months
|
|
Left ventricular ejection fraction (LVEF)
Prazo: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left atrial diameter (LAD)
Prazo: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Right atrial diameter (RAD)
Prazo: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left ventricular end-systolic diameter (LVESD)
Prazo: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left ventricular end-diastolic diameter (LVEDD)
Prazo: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
E/e'
Prazo: At baseline, 6-, 12- , 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12- , 24-month follow-ups
|
|
Mitral regurgitation severity
Prazo: At baseline, 6-, 12- , 24-month follow ups
|
Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe) |
At baseline, 6-, 12- , 24-month follow ups
|
|
Tricuspid regurgitation severity
Prazo: At baseline, 6-, 12-, 24- month follow-ups
|
Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe) |
At baseline, 6-, 12-, 24- month follow-ups
|
|
NT-pro BNP
Prazo: At baseline, before discharge, and 6-month follow-up
|
Standard transthoracic echocardiographic parameter |
At baseline, before discharge, and 6-month follow-up
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Atrial pacing capture threshold
Prazo: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Atrial sensing amplitude
Prazo: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Atrial pacing output
Prazo: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Procedural complications
Prazo: Perioperative
|
Safety Outcome |
Perioperative
|
|
Postoperative adverse events
Prazo: From implantation to regular follow-ups up to 24 months
|
Safety Outcome, including lead-related complications, thromboembolic events, etc. |
From implantation to regular follow-ups up to 24 months
|
|
Paced P-wave morphology
Prazo: From implantation to regular follow-ups up to 24 months
|
positive, negative, notched, and biphasic |
From implantation to regular follow-ups up to 24 months
|
|
Intrinsic P-wave morphology
Prazo: At baseline, implant, and regular follow-ups up to 24 months when intrinsic atrial rhythm is assessable
|
positive, negative, notched, and biphasic |
At baseline, implant, and regular follow-ups up to 24 months when intrinsic atrial rhythm is assessable
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- PSB-AF
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .